On a Mission to Hunt Down the Next Monster Healthcare Winners
My name is Marc Lichtenfeld.
I’m Senior Healthcare Analyst for The Oxford Club.
As a financial analyst, I’ve been written up in publications including The Wall Street Journal, and The Street.com, where I was a Senior Columnist.
Marketocracy – a leading research company that evaluates the investment industry – shows one of my model portfolios outperformed 99% of those tracked on their site based on 5-year performance.
I’ve spent the vast majority of my working days the past 15 years researching high-return opportunities in the biotech, healthcare and technology markets…
And my research has made some folks very large amounts of money, as you’ll see below.
How is that possible?
Of course it has a lot to do with my tens of thousands of hours of due diligence… and years of experience in the markets.
But it’s also thanks to the valuable time I spend talking with drug company executives, pharma industry insiders and hedge fund managers.
This kind of personal interaction can yield “advantages” not available to just about anyone else out there. For example…
- In 2008, my “in the field” contacts and extensive research uncovered certain unusual information about SIGA Technologies, a vaccine producer, and I promptly recommended the stock to my readers. In a little over a year, I closed out the position for a 97% gain.
- In 2009, I gathered critical insights regarding the management of Nektar Therapeutics, a biopharmaceutical firm, and followed up with a recommendation in March. Seven months later, after closing out the position, reader Jerry H. wrote: “You asked how I did on NKTR. I bought 4000 shares at $4.85 and sold them at $8.80. I will take that anytime.” Reader Bob W. added, “I bought NKTR at 4.06 and sold at 8.90, so I got a double.”
- In January 2010, I conducted some very special research on innovator Delcath Systems, which fights liver cancer… and my readers were glad I did. My subsequent recommendation produced triple digit-plus returns. Reader Brian N said, “I sold half my position of DCTH and made a 128% profit. I trust your recommendations.”
I doubt these kinds of gains would have been possible without my in-the-trenches investigation and analysis.
Numerous major investment firms and professionals rely on my research, as well, including…
- A San Francisco-based hedge fund with $8 billion under management…
- The Director of Research of a $450-million East Coast-based hedge fund…
- A Managing Director of a Fifth Avenue (New York) investment bank…
- A Northern California hedge fund whose primary investor is a household name billionaire…
- A New York-based institutional brokerage that features some of the largest hedge funds as its clients…
- And many more.
But I’m most proud of the tremendous returns I’ve brought to readers in the recent past.
Yet I believe the opportunities from this coming $4-trillion healthcare explosion stand to eclipse – by far – even my most successful prior recommendations.
Here are three specific opportunities I’m researching right now that could hand you a fortune in the coming months.
Page 3
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9
[cfsp name="joinnow"]